VISCOTRAUMA: Use of Viscoelastic Tests in the Treatment of Traumatic Induced Coagulopathy: a Pragmatic Randomized Clinical Trial.

Sponsor
A.O. Ospedale Papa Giovanni XXIII (Other)
Overall Status
Withdrawn
CT.gov ID
NCT03380767
Collaborator
(none)
0
1
2
21
0

Study Details

Study Description

Brief Summary

Trauma is the leading cause of death in young people. Trauma-induced coagulopathy (TIC) encompasses several aspects of traumatic bleeding. Monitoring of coagulopathy comprises use of Point-of-Care (POC) methods, such as thromboelastography (TEG) or Thromboelastometry (ROTEM) and conventional laboratory assays (platelet count, fibrinogen level, and PT or INR).

POC tests are thought to have a better performance on mortality and bleeding control than conventional tests. The aim of this study is to compare POC and conventional assays with plasma consumption as a primary outcome and 28 days mortality as a secondary one.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Trauma-induced coagulopathy treatment
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Pragmatic randomized controlled trialPragmatic randomized controlled trial
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Use of Viscoelastic Tests in the Treatment of Trauma-induced Coagulopathy: a Pragmatic Randomized Clinical Trial Comparing Viscoelastic Tests With Conventional Assays.
Anticipated Study Start Date :
Dec 1, 2019
Anticipated Primary Completion Date :
Jun 1, 2021
Anticipated Study Completion Date :
Sep 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: POC group

In this group, patients will be treated according to the information gathered by TEG or ROTEM assays.

Procedure: Trauma-induced coagulopathy treatment
Transfusion as needed according to the assay methodology

Experimental: Conventional group

In this group, patients will be treated according to the information gathered by conventional laboratory assays (platelet count, fibrinogen level, PT or INR and d dimer for fibrinolysis)

Procedure: Trauma-induced coagulopathy treatment
Transfusion as needed according to the assay methodology

Outcome Measures

Primary Outcome Measures

  1. Fresh frozen plasma consumption [3 years]

    In the POC group plasma consumption is estimated 20% less than in conventional assays group

Secondary Outcome Measures

  1. Mortality [28 days]

    28 days mortality

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion Criteria: all adult (> 18 years old) trauma patients treated in our Emergency Department with a TASH score > 18

Exclusion Criteria:
  • dead on arrival

  • no blood product administered after randomization

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ospedale Papa Giovanni XXIII Bergamo BG Italy 24127

Sponsors and Collaborators

  • A.O. Ospedale Papa Giovanni XXIII

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Stefano Magnone, Attending General Surgeon, A.O. Ospedale Papa Giovanni XXIII
ClinicalTrials.gov Identifier:
NCT03380767
Other Study ID Numbers:
  • Trauma Study
First Posted:
Dec 21, 2017
Last Update Posted:
Mar 3, 2021
Last Verified:
Mar 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Stefano Magnone, Attending General Surgeon, A.O. Ospedale Papa Giovanni XXIII
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 3, 2021